Transparency
Market Research Reports incorporated a definite business overview and
investigation inclines on “MDD,
Anxiety and Panic Disorder Therapeutics Market”.
This report likewise incorporates more illumination about fundamental
review of the business including definitions, requisitions and
worldwide business sector industry structure. Epidemiologic
studies have concluded that majority of the individuals experiencing
panic attack will also experience a major depression disorder (MDD)
and this factor increases the possibility of co-occurrence of panic
disorder. These disorders tend in functional disability along with
suicidal behavior in the patients and are in association with
depression and panic conditions. Anxiety symptoms include obsessive,
obtrusive, worried thoughts, irritability, confusion and difficulty
concentrating and frustration. Person with anxiety also feel
uncomfortable physical sensations, tense some characteristics such as
trembling, a racing heartbeat, sweating, difficulty breathing and
nausea. The sudden onset of such symptoms is often an indicator of a
severe panic attack. Anxiety can also lead to lightheadedness,
headaches, digestive problems and insomnia.
Browse
Full Report with TOC:
http://www.transparencymarketresearch.com/mdd-anxiety-panic-disorder-therapeutics.html
According
to National Comorbidity Survey Replication, the prevalence for an
anxiety disorder was about 18%, and for mood disorder it was 9.5%
every year. Lifetime prevalence for any anxiety disorder and MDD were
approximately 29% and 16.6%, respectively. Assuming a 50% comorbidity
rate, between 5% and 9% of the adult population has comorbid
depression-anxiety in a year’s time. The treatment against these
comorbid depression and anxiety disorder are cognitive-behavioral
therapy (CBT) as an effective psychological treatment but it needs
support from therapeutic drugs where anti-depressants are observed to
be the first-line of treatment for comorbid depression and anxiety
disorders.
But
in this disorder the anti-depressants may turn into panic attacks for
patients when they have undetected bipolar disorder which should be
analyzed by mapping the family history of patient before treatment.
According to World Health Organization (WHO), neuropsychiatric
disorders accounted for more than 13% of all medical disability
worldwide and for more than 27% of all noncommunicable disease in
2005. Depression alone produced 10% to 12% of all disability from
noncommunicable disease and approximately 5% of all disability
(noncommunicable, communicable, injury). Thus, comorbid anxiety and
depression may account for as much as 2% to 4% of all medical
disability worldwide. The antidepressants particularly used in this
treatment are serotonin-specific reuptake inhibitor (SSRI) such as
escitalopram, citalopram, fluvoxamine, paroxetine, fluoxetine,
sertraline and Serotonin-norepinephrine reuptake inhibitors (SNRI) is
venlafaxine that are observed to be the first-line pharmacotherapy
for depression and anxiety disorders.
The
recent updates regarding major depression disorder (MDD), anxiety and
panic disorder market is about to go through a vibrant phase with
forthcoming patent expiries for leading products such as BMS/Otsuka’s
Abilify and Eli Lilly's Cymbalta, and in January 2014 the recent
launch of, Lundbeck/Takeda's Brintellix a multimodal antidepressant.
The other devices present in the pipeline are Richter/Mitsubishi
Tanabe Pharma’s cariprazine, Naurex’s GLYX-13, Forest
(Actavis)/Gedeon and Alkermes’s ALKS-5461 along with antidepressant
therapies such as Lundbeck/Takeda’s tedatioxetine, e-Therapeutics’
ETS6103 and Euthymics Bioscience’s amitifadine. The overall major
depression disorder (MDD), anxiety and panic disorder market is about
to observe a significant growth in the market. As the drivers
impacting this market are primarily increasing the amount of stress
and lack of sleep in adult population that are having various
psychological problems.
Some
of the key players in the Major Depression Disorder (MDD), anxiety
and panic disorder market are Shire Plc, Forest Laboratories,
Novartis AG, Astra Zeneca Plc, Eli Lilly and Company, Pfizer, Inc.,
Janssen Pharmaceuticals, Inc. (JPI), BTG International (BTG), H.
Lundbeck A/S, Alexza Pharmaceuticals and others.
Read
More Reports on Pharmaceutical
Markets:
http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
This
research report analyzes this market depending on its market
segments, major geographies, and current market trends. Geographies
analyzed under this research report include
- North America
- Asia Pacific
- Europe
- Rest of the World
This
report provides comprehensive analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This
report is a complete study of current trends in the market, industry
growth drivers, and restraints. It provides market projections for
the coming years. It includes analysis of recent developments in
technology, Porter’s five force model analysis and detailed
profiles of top industry players. The report also includes a review
of micro and macro factors essential for the existing market players
and new entrants along with detailed value chain analysis.
Enquiry
before Buying @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2928
About
Us
Transparency
Market Research is a market intelligence company providing global
business information reports and services. Our exclusive blend of
quantitative forecasting and trends analysis provides forward-looking
insight for thousands of decision makers.
Followed
LinkedIn
:-https://www.linkedin.com/today/post/article/20140807054413-349336221-mdd-anxiety-and-panic-disorder-therapeutics-market
Contact:
Transparency
Market Research
90
State Street,
Suite
700,
Albany
NY — 12207
United
States
Tel:
+1-518-618-1030
USA — Canada
Toll Free 866-552-3453
Browse
Market Research Blogs:
0 comments:
Post a Comment